haloperidol has been researched along with Nerve Pain in 12 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Haloperidol (HAL) is a compound that shows a high affinity with these receptors, acting as an antagonist." | 5.46 | Haloperidol Decreases Hyperalgesia and Allodynia Induced by Chronic Constriction Injury. ( Espinosa-Juárez, JV; Jaramillo-Morales, OA; López-Muñoz, FJ, 2017) |
| "Haloperidol is an antipsychotic agent recently described as an antinociceptive drug able to mediate the antagonism of sigma-1 receptors while morphine is an opioid used in the treatment of neuropathic pain." | 1.62 | Haloperidol potentiates antinociceptive effects of morphine and disrupt opioid tolerance. ( Blanco-Hernández, Y; Espinosa-Juárez, JV; López-Muñoz, FJ; Mena-Valdés, LC, 2021) |
| "Patients with neuropathic pain are highly motivated for pain relief, and as motivational factors such as expectations of reward, as well as pain processing in itself, are related to the dopaminergic system, it can be speculated that dopamine release contributes to placebo effects in neuropathic pain." | 1.48 | Dopaminergic tone does not influence pain levels during placebo interventions in patients with chronic neuropathic pain. ( Baastrup, C; Benedetti, F; Grosen, K; Hall, KT; Jensen, TS; Kaptchuk, TJ; Moslemi, K; Petersen, GL; Price, DD; Skyt, I; Svensson, P; Vase, L, 2018) |
| "Haloperidol (HAL) is a compound that shows a high affinity with these receptors, acting as an antagonist." | 1.46 | Haloperidol Decreases Hyperalgesia and Allodynia Induced by Chronic Constriction Injury. ( Espinosa-Juárez, JV; Jaramillo-Morales, OA; López-Muñoz, FJ, 2017) |
| "Neuropathic pain is a serious chronic disorder caused by lesion or dysfunction in the nervous systems." | 1.36 | Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: de ( Hayashi, S; Kato, A; Mizuno, K; Morita, A; Nakata, E; Ohashi, K; Yamamura, K, 2010) |
| "20 patients with neuropathic pain syndromes due to tumor-infiltration, who had not responded to conventional analgesics including strong opioids, received additional combination anti-convulsant and anti-depressant treatment." | 1.28 | Anti-depressants and anti-convulsants for the treatment of neuropathic pain syndromes in cancer patients. ( Höffken, K; Kloke, M; Olbrich, H; Schmidt, CG, 1991) |
| " A dosing strategy for the combbination of clomipramine and haloperidol is described." | 1.26 | [The treatment of chronic pain symptoms with psychotropic drugs (author's transl)]. ( Kocher, R, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashi, S | 1 |
| Nakata, E | 1 |
| Morita, A | 1 |
| Mizuno, K | 1 |
| Yamamura, K | 1 |
| Kato, A | 1 |
| Ohashi, K | 1 |
| Tewes, B | 1 |
| Frehland, B | 1 |
| Schepmann, D | 1 |
| Schmidtke, KU | 1 |
| Winckler, T | 1 |
| Wünsch, B | 1 |
| Nelson, DW | 1 |
| Frost, JM | 1 |
| Tietje, KR | 1 |
| Florjancic, AS | 1 |
| Ryther, K | 1 |
| Carroll, WA | 1 |
| Dart, MJ | 1 |
| Daza, AV | 1 |
| Hooker, BA | 1 |
| Grayson, GK | 1 |
| Fan, Y | 1 |
| Garrison, TR | 1 |
| El-Kouhen, OF | 1 |
| Yao, B | 1 |
| Pai, M | 1 |
| Chandran, P | 1 |
| Zhu, C | 1 |
| Hsieh, GC | 1 |
| Meyer, MD | 1 |
| Díaz, JL | 1 |
| Cuberes, R | 1 |
| Berrocal, J | 1 |
| Contijoch, M | 1 |
| Christmann, U | 1 |
| Fernández, A | 1 |
| Port, A | 1 |
| Holenz, J | 1 |
| Buschmann, H | 1 |
| Laggner, C | 1 |
| Serafini, MT | 1 |
| Burgueño, J | 1 |
| Zamanillo, D | 1 |
| Merlos, M | 1 |
| Vela, JM | 1 |
| Almansa, C | 1 |
| Cao, X | 1 |
| Chen, Y | 2 |
| Zhang, Y | 1 |
| Lan, Y | 1 |
| Zhang, J | 1 |
| Xu, X | 1 |
| Qiu, Y | 1 |
| Zhao, S | 1 |
| Liu, X | 2 |
| Liu, BF | 2 |
| Zhang, G | 2 |
| Peng, Y | 1 |
| Zhang, Q | 1 |
| Welsh, WJ | 1 |
| Xiong, J | 1 |
| Zhuang, T | 1 |
| Ma, Y | 1 |
| Xu, J | 1 |
| Ye, J | 1 |
| Ma, R | 1 |
| Zhang, S | 1 |
| Hao, C | 1 |
| Mena-Valdés, LC | 1 |
| Blanco-Hernández, Y | 1 |
| Espinosa-Juárez, JV | 2 |
| López-Muñoz, FJ | 2 |
| Jaramillo-Morales, OA | 1 |
| Skyt, I | 1 |
| Moslemi, K | 1 |
| Baastrup, C | 1 |
| Grosen, K | 1 |
| Benedetti, F | 1 |
| Petersen, GL | 1 |
| Price, DD | 1 |
| Hall, KT | 1 |
| Kaptchuk, TJ | 1 |
| Svensson, P | 1 |
| Jensen, TS | 1 |
| Vase, L | 1 |
| Kocher, R | 1 |
| Kloke, M | 1 |
| Höffken, K | 1 |
| Olbrich, H | 1 |
| Schmidt, CG | 1 |
12 other studies available for haloperidol and Nerve Pain
| Article | Year |
|---|---|
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: de
Topics: Analgesics; Animals; Benzimidazoles; Drug Design; Drug Evaluation, Preclinical; Humans; Microsomes, | 2010 |
Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diols.
Topics: Analgesics; Animals; Benzazepines; Humans; Mice; Microsomes, Liver; Neuralgia; Piperidines; Rats; Re | 2010 |
Synthesis and evaluation of 2-amido-3-carboxamide thiophene CB₂ receptor agonists for pain management.
Topics: Amides; Analgesics; Animals; Biological Availability; Cell Line, Tumor; Dose-Response Relationship, | 2012 |
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
Topics: Animals; Brain; Female; Guinea Pigs; HEK293 Cells; Humans; Hyperalgesia; In Vitro Techniques; Male; | 2012 |
Synthesis and Biological Evaluation of Novel σ1 Receptor Ligands for Treating Neuropathic Pain: 6-Hydroxypyridazinones.
Topics: Analgesics, Non-Narcotic; Animals; Chemistry Techniques, Synthetic; Disease Models, Animal; Dose-Res | 2016 |
Novel Sigma 1 Receptor Antagonists as Potential Therapeutics for Pain Management.
Topics: Animals; Binding Sites; Blood-Brain Barrier; Drug Design; Guinea Pigs; Half-Life; Humans; Microsomes | 2021 |
Optimization of bifunctional piperidinamide derivatives as σ
Topics: Acetic Acid; Amides; Animals; Behavior, Animal; Dose-Response Relationship, Drug; Formaldehyde; Guin | 2021 |
Haloperidol potentiates antinociceptive effects of morphine and disrupt opioid tolerance.
Topics: Analgesics, Opioid; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergis | 2021 |
Haloperidol Decreases Hyperalgesia and Allodynia Induced by Chronic Constriction Injury.
Topics: Amines; Analgesics; Animals; Antipsychotic Agents; Chronic Disease; Constriction, Pathologic; Cycloh | 2017 |
Dopaminergic tone does not influence pain levels during placebo interventions in patients with chronic neuropathic pain.
Topics: Adult; Aged; Anesthetics, Local; Carbidopa; Chronic Pain; Dopamine; Dopamine Agents; Drug Combinatio | 2018 |
[The treatment of chronic pain symptoms with psychotropic drugs (author's transl)].
Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Bone Diseases; Clomipramine; Drug Therapy, C | 1976 |
Anti-depressants and anti-convulsants for the treatment of neuropathic pain syndromes in cancer patients.
Topics: Analgesics; Anticonvulsants; Antidepressive Agents; Clomipramine; Drug Therapy, Combination; Haloper | 1991 |